Abstracts tagged "Biologics"

Abstract Number: 195 • 2013 ACR/ARHP Annual Meeting
Major Cost Savings Associated With Reduced Biologic Dosing Frequency In Inflammatory Arthritis
Claire-Louise Murphy¹, Miriam O'Sullivan², Sohail Awan³, Shawn Chavrimootoo⁴, Clara Bannon³, Linzi Martin², Trevor Duffy², Eithne Murphy² and Maurice Barry², ¹Rheumatology, Connolly hospital, Dublin 15, Dublin, Ireland, ²Rheumatology, Connolly hospital, Dublin, Ireland, ³Blanchardstown, Connolly hospital, Dublin, Ireland, ⁴rheumatology, Connolly hospital, Dublin, Ireland
Background/Purpose: Biologic agents are highly effective in Inflammatory Arthritis (IA) but are extremely expensive. A sustained reduction in biologic dosing frequency would lead to major…
Abstract Number: 2821 • 2013 ACR/ARHP Annual Meeting
Evaluation Of Selective Manipulation Of The CD28 Co-Stimulation Pathway In The Rhesus Monkey Model Of Collagen-Induced Arthritis
Michel P.M. Vierboom¹, Elia Breedveld¹, Bert 't Hart¹, Flora Coulon² and Bernard Vanhove³, ¹Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, Netherlands, ²UMR-S 1064, Institut National de la Santé et de la Recherche Médicale, Nantes, France, ³Institut de Transplantation - Urologie - Néphrologie, INSERM UMR-S 1064, Nantes, France
Background/Purpose: T-cells are important in the pathogenesis of rheumatoid arthritis (RA). T-cell activation depends on at least two signals. Next to the first signal that…
Abstract Number: 2041 • 2013 ACR/ARHP Annual Meeting
Pregnancy Outcomes In Women Exposed To Golimumab
Amy G. Lau¹, Michael Clark¹, Diane D. Harrison¹, Anja Geldhof², Riikka Nissinen² and Marilyn Sanders¹, ¹Janssen Research & Development, LLC., Horsham, PA, ²Janssen Biologics Europe, Leiden, Netherlands
Background/Purpose: Rheumatologic conditions and inflammatory bowel disease can affect women of childbearing potential. Golimumab (GLM) is approved for rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing…
Abstract Number: 1427 • 2013 ACR/ARHP Annual Meeting
Discovery and Characterization Of ABT-122, An Anti-TNF/IL-17 DVD-Ig™ Molecule As a Potential Therapeutic Candidate For Rheumatoid Arthritis
Chung-Ming Hsieh¹, Carolyn Cuff², Edit Tarcsa³ and Margaret Hugunin⁴, ¹Biologics, AbbVie Pharmaceuticals, Worcester, MA, ²Immunology, AbbVie, Inc, Worcester, MA, ³Immunology, AbbVie Bioresearch Center, Worcester, MA, ⁴Molecular and Cellular Pharmacology, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: Rheumatoid arthritis (RA) is a serious autoimmune disease that significantly impacts patients’ quality of life. Several approved biologic drugs targeting tumor necrosis factor (TNF)…
Abstract Number: 463 • 2013 ACR/ARHP Annual Meeting
An Indirect Comparisons Analysis Between Biologic Disease Modifiers in The Treatment Of Rheumatoid Arthritis To Evaluate For Efficacy and Safety
Aaron C. Garza Romero¹, Elie Donath¹, Hernan Osorno¹ and Suresh Kumar², ¹Internal Medicine, University of Miami Miller School of Medicine Palm Beach Regional Campus, Atlantis, FL, ²Rheumatology, University of Miami Miller School of Medicine Palm Beach Regional Campus, Atlantis, FL
Background/Purpose: There are primarily six groups of biologic disease modifiers (BDM) for treatment of rheumatoid arthritis (RA): tumor necrosis factor inhibitors (infliximab (IFX), etanercept (ETN),…
Abstract Number: L7 • 2013 ACR/ARHP Annual Meeting
Improvement in Psoriasis Symptoms and Physical Functioning with Secukinumab Compared with Placebo and Etanercept in Subjects with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Results of a Subanalysis from the Phase 3 Fixture Study
Alice Gottlieb¹, Richard Langley², Sandra Philipp³, Ruvie Martin⁴, Charis Papavassilis⁵ and Shephard Mpfofu⁵, ¹Tufts Medical Center, Boston, MA, ²Dalhousie University, Halifax, NS, Canada, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Novartis Pharma AG, East Hanover, NJ, ⁵Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab (SEC; AIN457), a fully human anti–IL-17A monoclonal antibody, has demonstrated efficacy in phase 3 trials for treatment of plaque psoriasis and preliminary results…
Abstract Number: 2761 • 2013 ACR/ARHP Annual Meeting
Comparative Risks Of Herpes Zoster Among RA Patients Switching Biologics In The U.S. Medicare Program
Huifeng Yun¹, Fenglong Xie², Elizabeth S. Delzell¹, Lang Chen³, Emily Levitan¹, James Lewis⁴, Kenneth G. Saag⁵, Timothy Beukelman⁶, Kevin L. Winthrop⁷, John Baddley⁸ and Jeffrey R. Curtis⁹, ¹Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ⁸Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁹University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Several newer biologics have been approved for treatment of rheumatoid arthritis (RA) in the United States. However, their comparative risks of herpes zoster infection…
Abstract Number: 2042 • 2013 ACR/ARHP Annual Meeting
Pregnancy Outcomes In Women With Rheumatologic Conditions Exposed To Infliximab
Sirisha Kalari¹, Fredrik Granath², Chun-Yuan Guo¹, Diane D. Harrison¹, Gabriella Bröms², Anja Geldhof³, Riikka Nissinen³, Marilyn Sanders¹, Mika Gissler⁴, Lars Pedersen⁵, Henrik Toft Sorensen⁵ and Helle Kieler², ¹Janssen Research & Development, LLC., Horsham, PA, ²Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden, ³Janssen Biologics Europe, Leiden, Netherlands, ⁴Information Department, National Institute for Health and Welfare, Helsinki, Finland, ⁵Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: RA, AS, and PsA are approved indications for infliximab (IFX). In the US, IFX is a pregnancy Category B drug. For RA and some…
Abstract Number: 1414 • 2013 ACR/ARHP Annual Meeting
Final 5-Year Safety and Efficacy Results Of a Phase 3, Randomized Placebo-Controlled Trial Of Golimumab In Patients With Active Rheumatoid Arthritis Despite Prior Treatment With Methotrexate
Edward Keystone¹, Mark C. Genovese², Stephen Hall³, Pedro Miranda⁴, Sang-Cheol Bae⁵, Chenglong Han⁶, Timothy A. Gathany⁶, Yiying Zhou⁷, Stephen Xu⁸ and Elizabeth C. Hsia⁸, ¹University of Toronto/Mount Sinai Hospital, Toronto, ON, Canada, ²Division of Rheumatology, Stanford University, Palo Alto, CA, ³Cabrini Medical Centre, Melbourne, Australia, ⁴Universidad de Chile and Centro de Estudios Reumatologicos, Santiago de Chile, Chile, ⁵Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁶Janssen Global Services, LLC., Malvern, PA, ⁷Biostatistics, Janssen Research & Development, LLC., Spring House, PA, ⁸Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: The safety and efficacy of subcutaneous golimumab (GLM)+/-MTX has been evaluated through 2yrs in a phase 3 trial (GO-FORWARD) of pts with active rheumatoid…
Abstract Number: 477 • 2013 ACR/ARHP Annual Meeting
Golimumab Improves Patient-Reported Outcomes In Patients With Active Rheumatoid Arthritis
B Dasgupta¹, P Bertin², L Settas³, JE Fonseca⁴, V Wolff⁵, R Yao⁶, M Govoni⁷, N Vastesaeger⁸ and HH Weng⁶, ¹Southend University Hospital, Westcliff-on-Sea, United Kingdom, ²Hôpital Dupuytren, Limoges, France, ³AHEPA University Hospital of Thessaloniki, Thessaloniki, Greece, ⁴Lisbon Academic Medical Centre, Lisboa, Portugal, ⁵Hospital del Salvador, Santiago, Chile, ⁶Merck & Co., Inc., Whitehouse Station, NJ, ⁷MSD Italy, Rome, Italy, ⁸Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Rheumatoid arthritis (RA) has a substantial impact on patient quality of life (QOL), physical functioning, and other outcomes important to patients. This subanalysis of…
Abstract Number: 2768 • 2013 ACR/ARHP Annual Meeting
Intravenous Golimumab Inhibits Radiographic Progression and Maintains Clinical Efficacy and Safety In Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: 2-Year Results Of a Phase 3 Trial Of Intravenous Golimumab
Michael E. Weinblatt¹, Clifton O. Bingham III², Alan M. Mendelsohn³, Lilianne Kim⁴, Kim Hung Lo⁴, Lenore Noonan³, Daniel Baker⁴ and Rene Westhovens⁵, ¹Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Immunology, Janssen Research & Development, LLC., Spring House, PA, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵Rheumatology, University Hospital KU Leuven, Leuven, Belgium
Background/Purpose: To evaluate long-term clinical/radiographic efficacy of IV GLM 2mg/kg+MTX in active RA despite MTX through wk112. Methods: 592 pts with active RA (≥6/66 SJC,…
Abstract Number: 2043 • 2013 ACR/ARHP Annual Meeting
Perinatal Exposure To Traditional and Biologic Disease Modifying Antirheumatic Drugs In Rheumatic Diseases: A Systematic Review Of Congenital Outcomes
Corisande Baldwin¹, Sharan Rai², J. Antonio Avina-Zubieta^2,3 and Mary De Vera^2,4, ¹Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Centre of Canada, Richmond, BC, Canada, ³Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Despite the high incidence of rheumatic diseases during reproductive years, little is known about the perinatal impact of traditional and biologic disease modifying antirheumatic…
Abstract Number: 1416 • 2013 ACR/ARHP Annual Meeting
Safety and Efficacy Of Subcutaneous Golimumab In Chinese Patients With Active Rheumatoid Arthritis Despite MTX Therapy: Results From a Randomized, Placebo-Controlled, Phase 3 Trial
Zhanguo Li¹, Fengchun Zhang², Jonathan Kay³, Kaiyin Fei⁴, Chenglong Han⁵, Yanli Zhuang⁴, Zhong Wu⁴ and Elizabeth C. Hsia⁴, ¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ²Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵Janssen Global Services, LLC., Malvern, PA
Background/Purpose: Assess safety and efficacy of GLM+MTX over 1yr in a multicenter, randomized, placebo (PBO)-controlled study of Chinese pts with active RA despite MTX therapy.…
Abstract Number: 479 • 2013 ACR/ARHP Annual Meeting
Attainment Of Remission, Functional, and Quality Of Life Improvements With Golimumab Treatment In Rheumatoid Arthritis Are Associated With Patient Expectations
B Dasgupta¹, B Combe², I Louw³, J Wollenhaupt⁴, C Zerbini⁵, A Beaulieu⁶, H Schulze-Koops⁷, P Durez⁸, V Wolff⁹, R Yao¹⁰, HH Weng¹⁰, M Govoni¹¹ and N Vastesaeger¹², ¹Southend University Hospital, Westcliff-on-Sea, United Kingdom, ²Hôpital Lapeyronie, Montpellier, France, ³Panorama Medical Centre, Cape Town, South Africa, ⁴Schön-Klinik, Hamburg, Germany, ⁵Hospital Heliópolis, Serviço de Reumatologia, São Paulo, Brazil, ⁶Centre de Rhumatologie, St-Louis, QC, Canada, ⁷University of Munich, Munich, Germany, ⁸Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁹Hospital del Salvador, Santiago, Chile, ¹⁰Merck & Co., Inc., Whitehouse Station, NJ, ¹¹MSD Italy, Rome, Italy, ¹²Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Golimumab (GLM) and other tumor necrosis factor antagonists are used as add-on therapy for patients with rheumatoid arthritis (RA) who have not responded to…
Abstract Number: 2740 • 2013 ACR/ARHP Annual Meeting
High Efficacy Of Toll-Like Receptor 4 Targeting In Murine and Humanized Models Of Rheumatoid Arthritis In Comparison With IL-1 and TNF Inhibitors
Shahla Abdollahi-Roodsaz¹, Marije I. Koenders², Leo A. Joosten³, Fons A. van de Loo⁴ and Wim B. van den Berg¹, ¹Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ³Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ⁴Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands
Background/Purpose: Increased expression of Toll-like Receptor (TLR) 4 and its endogenous agonists in rheumatoid joints suggest involvement in rheumatoid arthritis (RA). The aim of this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].